View : 91 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author이민종-
dc.date.accessioned2021-06-07T16:31:27Z-
dc.date.available2021-06-07T16:31:27Z-
dc.date.issued2021-
dc.identifier.issn1936-0533-
dc.identifier.otherOAK-29365-
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/257625-
dc.description.abstractBackground/Aim: We investigated the effect of non-selective β-blockers (NSBB) in real-world situations and whether low-dose NSBB is beneficial compared to maximally tolerated doses. Methods: We performed a retrospective study of 740 patients with cirrhosis requiring prophylactic treatment of esophageal varices: 473 primary prophylaxis (PP: NSBB = 349, non-NSBB = 124) and 267 secondary prophylaxis (SP: NSBB = 200, non-NSBB = 67). The NSBB group was divided into low-dose (≤ 80 mg/day) and high-dose (> 80 mg/day). Results: In the PP group, NSBB treatment reduced mortality and showed the most pronounced effect in patients with moderate/severe ascites (hazard ratio [HR], 0.46; p < 0.01), HVPG ≥ 16 mmHg (HR, 0.53; p = 0.04), or CTP class B/C (HR, 0.46; p < 0.01) but not in those with no/mild ascites, HVPG < 16 mmHg, or CTP class A. Low-dose NSBB group showed a significant reduction in mortality compared with non-NSBB (moderate/severe ascites: HR, 0.61; p = 0.02 and CTP class B/C: HR, 0.41; p < 0.01) and the effect size was stronger than the high-dose NSBB. NSBB was associated with a reduced risk of infection (HR, 0.36; p = 0.01). In the SP group, NSBB prolonged survival in patients with moderate/severe ascites (HR, 0.56; p = 0.02), HVPG ≥ 16 mmHg (HR, 0.42; p < 0.01), or CTP class B/C (HR, 0.52; p < 0.01). Low-dose NSBB was more beneficial with 56% risk reduction (p < 0.01) of mortality compared with 33% risk reduction in the high-dose NSBB (p = 0.05). Conclusion: NSBB therapy was associated with longer survival in PP and SP groups who had an advanced stage of cirrhosis. Moreover, low-dose NSBB exhibited a better benefit than a standard-titrated high-dose NSBB with better tolerability. © 2021, Asian Pacific Association for the Study of the Liver.-
dc.description.sponsorshipKim, M.Y.; Division of Gastroenterology and Hepatology, 20, Ilsan-ro, South Korea; email: drkimmy@yonsei.ac.kr-
dc.languageEnglish-
dc.publisherSpringer-
dc.subjectAscites-
dc.subjectEsophageal varix-
dc.subjectHepatic venous pressure gradient-
dc.subjectLiver cirrhosis-
dc.subjectLow-dose non-selective β-blockers-
dc.subjectNonselective β-blockers-
dc.subjectPortal hypertension-
dc.subjectSeverity-
dc.subjectSurvival-
dc.subjectTreatment-
dc.titleThe longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study-
dc.typeArticle-
dc.relation.issue2-
dc.relation.volume15-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.startpage424-
dc.relation.lastpage436-
dc.relation.journaltitleHepatology International-
dc.identifier.doi10.1007/s12072-021-10160-3-
dc.identifier.wosidWOS:000640728600001-
dc.identifier.scopusid2-s2.0-85104813316-
dc.author.googleKang S.H.-
dc.author.googleLee M.-
dc.author.googleKim M.Y.-
dc.author.googleLee J.H.-
dc.author.googleJun B.G.-
dc.author.googleKim T.S.-
dc.author.googleChoi D.H.-
dc.author.googleSuk K.T.-
dc.author.googleKim Y.D.-
dc.author.googleCheon G.J.-
dc.author.googleKim D.J.-
dc.author.googleBaik S.K.-
dc.contributor.scopusid이민종(55917792000)-
dc.date.modifydate20220114081001-
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE